Rapid Safety Assessment of SARS-CoV-2 Vaccines in EU Member States using Electronic Health Care Data Sources (COVID Vaccine Monitor-CVM study): Final Study Report for WP3 (electronic health record data)
Creators
-
Durán, Carlos E.1
- Messina, Davide2
-
Gini, Rosa2
-
Riefolo, Fabio3
- Aragón, María4
- Belitser, Svetlana5
-
Bissacco, Carlo Alberto4
-
Bots, Sophie H.5
-
de Burgos, Airam6
-
Carreras-Martínez, Juan José7
- Correcher-Martínez, Elisa7
- Douglas, Ian8
- Garcia-Poza, Patricia6
- Girardi, Anna2
-
Herings, Ron9
-
Hoxhaj, Vjola1
-
Huerta, Consuelo6
- Hyeraci, Giulia2
- Ientile, Valentina10
- Ingrasciotta, Ylenia10
- Limoncella, Giorgio2
-
Lupattelli, Angela11
-
Maglanoc, Luigi11
- Martin, Ivonne1
- Martin, Mar6
-
Mira-Iglesias, Ainara7
- Mohammadi, Sima1
- Molero, Eva3
-
Nordeng, Hedvig11
-
Oberski, Daniel1
-
Overbeek, Jetty9
-
Pallejà, Meritxell4
-
Riera-Arnau, Judit1
- Santacà, Katia12
-
Siiskonen, Satu5
-
Souverein, Patrick5
-
Schultze, Anna8
- Swart, Karin9
-
Trifirò, Gianluca10
- Urchueguía, Arantxa7
-
Villalobos, Felipe4
- Weibel, Daniel1
- Zhao, Jing11
- Klungel, Olaf5
-
Sturkenboom, Miriam1
- 1. University Medical Centre Utrecht, NL
- 2. Agenzia Regionale Sanità Toscana, Florence, IT
- 3. Teamit Institute, ES
- 4. Institut de Recerca en Atenció Primària Jordi Gol, ES
- 5. Universiteit Utrecht, NL
- 6. Spanish Agency on Medicines and Medical Devices (AEMPS), ES
- 7. Foundation for the Promotion of Health and Biomedical Research of Valencia Region (FISABIO)
- 8. London School of Hygiene & Tropical Medicine, UK
- 9. PHARMO Institute, NL
- 10. INSPIRE srl, IT
- 11. University of Oslo (UiO), NO
- 12. University of Verona, IT
Description
In January 2021, the European Medicines Agency (EMA) launched a tender for safety monitoring of COVID-19 vaccines in the EU. The EU PE & PV and the VAC4EU network received and implemented the tender, which had two objectives, the first was to implement a prospective cohort for safety monitoring in more than 10 countries and the second was signal strengthening. This report is focusing on the second objective. Based on the technical specifications, signal strengthening meant the collection of additional information to further characterise the incidence of the safety concerns in comparison to its expected incidence in non- vaccinated populations or suitable comparator populations. Request of signal strengthening capacity was translated into two objectives: i) to create and assess readiness of electronic healthcare record data sources for rapid evaluation of safety signals by providing an overview of the methods to identify COVID-19 vaccine exposure in data sources, monitoring the number of individuals exposed to any COVID-19 vaccine, and the generation of updated background rates for Adverse Events of Special Interest, and ii) to conduct rapid safety assessment studies using electronic healthcare records and support EMA safety assessments.
Notes
Files
D4.2_CVM_FinalReport_WP3only_20230814.pdf
Files
(7.1 MB)
Name | Size | Download all |
---|---|---|
md5:ab126e874dec092a0ee73c88df269232
|
7.1 MB | Preview Download |
Additional details
Related works
- Cites
- Software: 10.5281/zenodo.8272058 (DOI)
- Other: 10.5281/zenodo.8244051 (DOI)
- Journal article: 10.3389/fphar.2022.1038043 (DOI)
- Is supplemented by
- Dataset: 10.5281/zenodo.8199481 (DOI)